Prostate Cancer
New Approaches to Immunotherapy for Metastatic Castration-Resistant Prostate Cancer
Myeloma
Advances in CAR T-Cell Therapy for the Treatment of Multiple Myeloma
Nina Shah, MD
H&O What is the rationale for the use of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma? NS Multiple myeloma cells express B-cell maturation […]
In This Issue
Ovarian Cancer
The Current Status of Secondary Cytoreduction in Ovarian Cancer: A Systematic Review
Daniel Margul, MD, PhD, Robert L. Coleman, MD, and Thomas J. Herzog, MD
Leukemia
Richter Transformation of Chronic Lymphocytic Leukemia in the Era of Novel Agents
Yucai Wang, MD, PhD, and Wei Ding, MD, PhD
Ovarian Cancer
Update on Drugs in Advanced Ovarian Cancer
David O’Malley, MD
Letter From the Editor
Letter From the Editor: The Other “C” Word
Daniel J. George, MD
From Recent Issues
Colorectal Cancer
How We Treat Left-Sided vs Right-Sided Colon Cancer
Learning Objectives • To understand the biological and clinical differences between left-sided and right-sided colon cancer; • To identify appropriate therapies for patients with metastatic […]
Oncology
Providing Oncology Care During the COVID-19 Pandemic
H&O What has it been like practicing oncology in Washington state over the past few months? GL Most of my insights are based on the […]
Drug Development
Strategies to Overcome Resistance to PD-1 Inhibitors
H&O How do programmed death 1 (PD-1) inhibitors work? TG There is a growing list of antibodies that target either the PD-1 receptor or the ligand […]
Supplements
CLL
The Evolving Use of Minimal Residual Disease (MRD) Assessment in Chronic Lymphocytic Leukemia
Abstract: The treatment of chronic lymphocytic leukemia (CLL) has changed remarkably throughout the past decade, with patients achieving deeper and more durable responses. Importantly, this clinical activity […]
hematologic malignancies
Clinical Actionability of Measurable Residual Disease (MRD) Assessment in the Management of Patients With Hematologic Malignancies: A Case-Based Monograph
Abstract: New treatments for hematologic malignancies have led to outcomes that are outpacing the ability of traditional measures of response to accurately capture a patient’s depth of […]
B-Cell Malignancies
Highlights in B-Cell Malignancies From the 61st American Society of Hematology Annual Meeting
Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients With Chronic Lymphocytic Leukemia: Extended Follow-Up From the E1912 Trial Chemoimmunotherapy consisting of […]
Prostate Cancer
Adjuvant Therapy in High-Risk Prostate Cancer
Abstract: Although the prognosis in patients with localized prostate cancer is positive overall, high-risk localized disease is responsible for significant cancer-related morbidity and mortality following […]
The Use of Multiparametric MRI in Diagnosis and Active Surveillance of Prostate Cancer
H&O When is multiparametric magnetic resonance imaging used in the diagnosis of prostate cancer? TP We have the option of using multiparametric magnetic resonance imaging […]
First-Line Use of Novel Hormonal Agents in Prostate Cancer: A Critical Appraisal
Abstract: Castration has been the hallmark of the treatment of advanced prostate cancer for nearly a century. Conventional surgical or medical castration for the management […]